Implications of step for improved diabetes control: A payer perspective

American Journal of Pharmacy Benefits

Volumn 3, Issue 5, 2011, Pages 257-262

  Lonigro, Robert ^a   Sredzinski, Marcus ^a  

^a CeltiCare Health Plan of Massachusetts   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; GLYCOSYLATED HEMOGLOBIN; INSULIN;

ARTICLE; BLOOD GLUCOSE MONITORING; CLINICAL EFFECTIVENESS; COST CONTROL; COST MINIMIZATION ANALYSIS; DIABETES CONTROL; DIABETES MELLITUS; DOCTOR PATIENT RELATION; GLUCOSE BLOOD LEVEL; GLUCOSE TOLERANCE TEST; GLYCEMIC CONTROL; HEALTH CARE COST; HEALTH CARE PLANNING; HEALTH INSURANCE; HEALTH PROGRAM; HUMAN; MANAGED CARE ORGANIZATION; OUTCOME ASSESSMENT; PATIENT ASSESSMENT; PATIENT EDUCATION; PRIMARY MEDICAL CARE; SELF MONITORING; TOTAL QUALITY MANAGEMENT;

EID: 84859741312     PISSN: 19454481     EISSN: 21642494     Source Type: Journal    
DOI: None     Document Type: Article

References (12)

1. Polonsky WH, Fisher L, Schikman CH, et al. Structured self-monitoring of blood glucose significantly reduces A1C levels in poorly controlled, noninsulin-treated type 2 diabetes: results from the Structured Testing Program study. Diabetes Care. 2011;34(2):262-267.
2. Roche Diagnostics. ACCU-CHEK 360° View printable tool. https://www.accuchek.com/us/data-management/360-view-printable-tool.html. Accessed July 12, 2011.
3. Zhang P, Zhang X, Brown J, et al. Global healthcare expenditure on diabetes for 2010 and 2030. Diabetes Res Clin Pract. 2010;87(3):293-301.
4. Gray A, Raikou M, McGuire A, et al. Cost effectiveness of an intensive blood glucose control policy in patients with type 2 diabetes: economic analysis alongside randomised controlled trial (UKPDS 41). United Kingdom Prospective Diabetes Study Group. BMJ. 2000;320(7246):1373-1378.
5. Aagren M, Luo W. Association between glycemic control and short-term healthcare costs among commercially insured diabetes patients in the United States. J Med Econ. 2011;14(1):108-114.
6. National Diabetes Information Clearinghouse. National diabetes statistics, 2011. http://diabetes.niddk.nih.gov/dm/pubs/statistics/. Accessed August 22, 2011.
7. Genuth S, Eastman R, Kahn R, et al. American Diabetes Association. Implications of the United Kingdom prospective diabetes study. Diabetes Care. 2003;26(suppl 1):S28-S32.
8. Stratton IM, Adler AI, Neil HA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ. 2000;321(7258):405-412.
9. Gilmer TP, O'Connor PJ, Rush WA, et al. Predictors of health care costs in adults with diabetes. Diabetes Care. 2005;28(1):59-64.
10. Gray AM, Clarke P. The economic analyses of the UK prospective diabetes study. Diabet Med. 2008;25(suppl 2):47-51.
11. Shetty S, Secnik K, Oglesby AK. Relationship of glycemic control to total diabetes-related costs for managed care health plan members with type 2 diabetes. J Manag Care Pharm. 2005;11(7):559-564.
12. Grumbach K, Grundy P. Outcomes of Implementing Patient Centered Medical Home Interventions: A Review of the Evidence From Prospective Evaluation Studies in the United States. www.pcpcc.net/files/evidence_outcomes_in_pcmh.pdf. Updated November 16, 2010. Accessed August 22, 2011.